Polyrizon Ltd. PLRZ
11.25 USD -0.15 (-1.36%)
Nov 4, 2026, 12:07 PM EST
11.00 Day range 11.25
2.88 52-week range 18.20
- YTD
- +32.51%
- 1 year
- +90.68%
- Market cap
- 27.32M
- EPS (ttm)
- -4.97
- Shares out
- 4.19M
- YTD return
- +32.51%
- 1-year return
- +90.68%
- Volume
- 3.30K
- Avg volume
- 49.25K
- Open
- 11.00
- Previous close
- 11.41
- Day's range
- 11.00 – 11.25
- 52-week range
- 2.88 – 18.20
1D -0.10 (-0.92%)
Key statistics
- Enterprise value
- 5.46M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 23.00K
- Total debt
- 151.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 1.17
- 200-day average
- 1.17
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PLRZ Revenue — annual 0
PLRZ Net income — annual -3.33M
PLRZ EPS — annual -4.90
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- polyrizon-biotech.com
News
Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens 
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker 
12 Health Care Stocks Moving In Monday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Polyrizon Files New US Divisional Patent Application With USPTO, Further Expanding Its IP Portfolio Relating To Proprietary Mucoadhesive Technology 
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform - Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker 
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Your note
Sign in to keep a note on PLRZ — it syncs with the Stock Master app.